Malignant neoplasm of breast, HER2-positive (controls excluding all cancers)

C3_BREAST_HER2PLUS_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector
diagram bullet

Apply sex-specific rule

Sex only females

diagram downward connector
diagram bullet

Check conditions

RX_HER2PLUS

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C50
Cause of death: ICD-9 174
Cause of death: ICD-8 174
Cancer registry: Topography ICD-O-3 C50
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes ANY

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

-

diagram downward connector
C3_BREAST_HER2PLUS_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE
Control conditions not RX_HER2PLUS

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF5

Similar endpoints

List of similar endpoints to Malignant neoplasm of breast, HER2-positive (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

None

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals - - -
Unadjusted prevalence (%) - - -
Mean age at first event (years) - - -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: C3_BREAST_HER2PLUS_EXALLC – Malignant neoplasm of breast, HER2-positive (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Malignant neoplasm of breast, HER2-positive (controls excluding all cancers)

Endpoint not on priority list, no data to show.